methyl 8-hydroxy-2-naphthoate | 115399-09-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 8-hydroxy-2-naphthoate
• 英文别名: 7-methoxycarbonyl-1-naphthol；8-hydroxy-[2]naphthoic acid methyl ester；8-Hydroxy-[2]naphthoesaeure-methylester；methyl 8-hydroxy-2-naphthalene carboxylate；methyl 8-hydroxynaphthalene-2-carboxylate
• CAS: 115399-09-2
• 化学式: C₁₂H₁₀O₃
• 分子量: 202.21
• InChiKey: VCLWTCIPOBHLQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  368.5±15.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 8-hydroxy-2-naphthoate 在 四(三苯基膦)钯 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 89.0h， 生成 methyl 8-(2-chloro-6-fluorophenyl)-2-naphthalene carboxylate
  参考文献：
  名称：

  EP2394987

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl (1R,8S)-11-oxatricyclo[6.2.1.02,7]undeca-2(7),3,5,9-tetraene-4-carboxylate 在 dichlorotricarbonylruthenium(II) dimer 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 48.0h， 生成 methyl 8-hydroxy-2-naphthoate 、 methyl 5-hydroxy-2-naphthoate
  参考文献：
  名称：

  Isomerization of 7-Oxabenzonorbornadienes into Naphthols Catalyzed by [RuCl₂(CO)₃]₂

  摘要：

  Ruthenium-catalyzed isomerization of 7-oxanorbornadienes into naphthols was investigated. Among the various ruthenium catalysts tested, [RuCl2(CO)(3)](2) gave the highest yields in the isomerization, and various substituted naphthols were synthesized in moderate to excellent yields. Both symmetrical and Unsymmetrical 7-oxanorbornadienes were employed in the Study, and moderate to excellent regioselectivities were observed.

  DOI：

  10.1021/jo901504n

文献信息

• Ligand and counteranion enabled regiodivergent C–H bond functionalization of naphthols with α-aryl-α-diazoesters
  作者：Zhunzhun Yu、Yongfeng Li、Peichao Zhang、Lu Liu、Junliang Zhang

  DOI：10.1039/c9sc01657k

  日期：——

  an unprecedented ligand and counteranion-controlled and site-selectivity switchable direct C–H bond functionalization of unprotected naphthols with α-aryl-α-diazoesters was developed. In this transformation, site selectivities are realized by turning on/off the coordination between metal complexes and hydroxy groups. The preliminary mechanism revealed that the interaction between the hydroxy group

  在这里，开发了一种空前的配体和对阴离子控制的和位点选择性可转换的未保护的萘酚与α-芳基-α-二重氮酯的直接C–H键直接官能化。在该转化中，通过打开/关闭金属络合物与羟基之间的配位来实现位点选择性。初步机理表明，羟基与金催化剂之间的相互作用在切换金卡宾的位点选择性中起着关键作用。该协议可能为C–H键功能化提供一种新颖的设计。
• Organic Compounds
  申请人：Herold Peter

  公开号：US20080058320A1

  公开（公告）日：2008-03-06

  The invention relates to novel amino alcohols of the general formula (I) where X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  本发明涉及一种新型的氨基醇，其通式为(I)，其中X，R1，R2，R3，R4，R5和R6分别如详细描述中所定义，以及其制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。
• Organic compounds
  申请人：Novartis AG

  公开号：US07868036B2

  公开（公告）日：2011-01-11

  The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  本发明涉及一种新型氨基醇，其一般式为(I)，其中X、R1、R2、R3、R4、R5和R6在说明书中详细定义，以及它们的制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。
• ACYLGUANIDINE DERIVATIVES
  申请人：Kinoyama Isao

  公开号：US20110306621A1

  公开（公告）日：2011-12-15

  An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on a serotonin 5-HT 5A receptor modulating action. It was confirmed that acylguanidine derivatives, which has the characteristic structure in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent 5-HT 5A receptor modulating action and excellent pharmacological action based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

  本发明的目的是提供一种基于5-羟色胺5-HT5A受体调节作用的治疗或预防痴呆症、精神分裂症的优良药剂。经确认，酰基胍衍生物具有特征结构，其中胍基通过羰基和环状基团与萘的一个环结合，另一个环上结合环状基团，表现出强效的5-HT5A受体调节作用和优良的药理作用。本发明可用作治疗或预防痴呆症、精神分裂症、双相障碍或注意力缺陷多动障碍的优良药剂。
• Farnesoid X Receptor Agonists
  申请人：Deaton David Norman

  公开号：US20100249179A1

  公开（公告）日：2010-09-30

  The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.

  本发明提供了新型异噁唑化合物、制药组合物、治疗用途和制备方法。